NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Centene Corporation ("Centene" or the "Company") (NYSE: CNC) between December 12, 2024 and June 30, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Centene securities, and/or would like to discuss your legal rights and options please visit Centene Co ...

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 2: Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 3: Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates [5]. - Following this news, Centene's stock price fell by $22.87 per share, a decline of over 40%, from $56.65 on July 1, 2025, to $33.78 on July 2, 2025 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Centene securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The deadline to move the Court to serve as lead plaintiff is September 8, 2025, with the lead plaintiff acting on behalf of other class members [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [3] Group 3: Case Allegations - The lawsuit alleges that Centene's defendants provided misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share for the 2025 fiscal year [4] - Defendants reportedly made positive statements about Centene's enrollment and morbidity rates while concealing adverse facts, leading to investor damages when the truth was revealed [4]

Core Viewpoint - A securities class action lawsuit has been filed against Centene Corporation for allegedly making materially false and misleading statements regarding its business operations and market performance during the specified Class Period from December 12, 2024, to June 30, 2025 [1][2]. Group 1: Allegations Against Centene - The lawsuit claims that Centene's management misrepresented the company's marketplace share, indicating lower-than-expected enrollment and increased market morbidity [2]. - It is alleged that the statements made by Centene's management about the company's business and prospects were materially false and lacked a reasonable basis throughout the Class Period [2]. Group 2: Lead Plaintiff Process - Investors in Centene have until September 8, 2025, to apply to be appointed as lead plaintiff representatives in the class action [3]. - The lead plaintiff will represent the interests of all class members and is typically the investor or group of investors with the largest financial stake in the case [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the case and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]. - The firm encourages affected Centene investors to reach out for more information regarding the lawsuit [4].

Group 1 - Centene Corp (CNC) and Molina Healthcare Inc (MOH) are experiencing stock price increases following Berkshire Hathaway's investment in UnitedHealth Group (UNH) [1] - CNC shares rose by 4.4% to $28.11, marking its third gain in four sessions, after previously hitting a low of $24 due to a negative outlook for 2025 [2] - MOH shares increased by 3.4% to $165.03, recovering from a low of $150 after a significant drop post-earnings [3] Group 2 - Despite recent challenges, options traders are showing a bullish sentiment towards both CNC and MOH, with CNC's put/call open interest ratio in the 10th percentile of its annual range and MOH's ratio higher than only 19% of readings from the past year [4]

NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit. Investors have until September 8, 2025, to ask the ...

Core Insights - Membership growth is a fundamental driver of Centene Corporation's earnings model, with each additional enrollee contributing directly to premium revenues despite rising costs [1][2][3] - As of June 30, 2025, Centene's total membership reached 28 million, supported by strong enrollment in Marketplace, Individual and Commercial Group, Medicare, and Medicare PDP plans [2][9] - The company is expanding its Medicare Advantage presence through its WellCare platform, introducing plans in new counties and enhancing star ratings [2][3] Membership Growth and Strategy - Centene's membership growth enhances its scale, profitability, and resilience, allowing it to navigate market uncertainties with a diverse payer mix [3] - Ongoing membership momentum is driven by product innovation, geographic expansion, and community-focused retention strategies [3] - Although Medicaid enrollment has softened, the company continues to see growth in other segments, particularly in Medicare Advantage [2][3] Competitive Landscape - Humana Inc. is also experiencing membership growth, particularly in Medicare Advantage, with a projected increase of 175,000-250,000 in state-based contract membership in 2025 [4] - UnitedHealth Group is witnessing robust growth in medical membership, driven by demand for commercial and government-supported health plans [5] Financial Performance - Centene's shares have lost 55.3% year to date, underperforming the industry average [8] - The company trades at a forward price-to-earnings ratio of 7.2, significantly below the industry average of 12.1 [9][12] - Recent consensus estimates for Centene's EPS have been revised downward for the third and fourth quarters of 2025, indicating potential challenges ahead [13][15]

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centene Corporation (NYSE: CNC). CONTACT: CLASS PERIOD: December 12, 2024 to June 30, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors be ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Group 1: Allegations and Impact - The class period for the lawsuit is from December 12, 2024, to June 30, 2025 [3]. - The complaint alleges that Centene's management made overwhelmingly positive statements while concealing material adverse facts about the company's performance [3]. - Following the withdrawal of the 2025 guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Group 2: Financial Adjustments - Centene's preliminary analysis indicated that its overall market growth across 22 states, representing 72% of its marketplace membership, was lower than expected [3]. - The company adjusted its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75 [3]. Group 3: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by September 8, 2025 [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4].

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit. Investors have until September 8, 2025, to ask the ...